Skip to main content
. 2019 Sep 4;9:12760. doi: 10.1038/s41598-019-49251-5

Table 3.

Response to T-DM1 in 15 HER2-positive breast cancer patients.

Response N (%)
Complete response 4 (26.7%)
Partial response 7 (46.6%)
Stable disease 1 (6.7%)
Progressive disease 3 (20%)